J&J Spots Potential Of Fate’s Stem Cells, Signs Cancer Deal Worth Up To $3bn

Another Next-Generation Approach to CAR-Ts

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.